Hyeong Cheon Park

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Jürgen Floege, Sean Barbour, Daniel Cattran et al. · Kidney International · 2019 · 257 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Jodie L. Babitt, Michele F. Eisenga, Volker H. Haase et al. · Kidney International · 2021 · 204 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran et al. · Kidney International · 2019 · 181 citations · Full text